28033-63-8

Basic information

• Product Name: 2-METHOXYPHENYLACETYL CHLORIDE
• Synonyms: 2-METHOXYPHENYLACETYL CHLORIDE;2-(2-Methoxyphenyl)acetyl chloride;2-Methoxybenzeneacetyl chloride;o-Methoxyphenylacetyl chloride
• CAS NO: 28033-63-8
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.62
• Mol File: 28033-63-8.mol
• Article Data: 44

Chemical Properties

• Boiling Point: 152℃ (20 Torr)
• Flash Point: 95.1 °C
• Appearance: /
• Density: 1.192 g/cm³
• Vapor Pressure: 0.0163mmHg at 25°C
• Refractive Index: 1.524
• CAS DataBase Reference: 2-METHOXYPHENYLACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXYPHENYLACETYL CHLORIDE(28033-63-8)
• EPA Substance Registry System: 2-METHOXYPHENYLACETYL CHLORIDE(28033-63-8)

Safety Data

• Hazardous Substances Data: 28033-63-8(Hazardous Substances Data)

Usage

General Description

2-Methoxyphenylacetyl chloride is a chemical compound with the formula C9H9ClO2. It is a clear, colorless liquid that is used in the synthesis of pharmaceuticals and agrochemicals. 2-METHOXYPHENYLACETYL CHLORIDE is an acetylating agent, meaning it is commonly used to attach an acetyl group to other molecules in chemical reactions. It is also a versatile intermediate in the production of various organic compounds, including pharmaceuticals and fragrances. 2-Methoxyphenylacetyl chloride is known to be a skin and eye irritant, and it should be handled with care and proper protective equipment.

InChI:InChI=1/C9H9ClO2/c1-12-8-5-3-2-4-7(8)6-9(10)11/h2-5H,6H2,1H3

Upstream product

• 121985-99-7 2-hydroxy-2-(2-methoxyphenyl)acetonitrile 
• 7169-17-7 2-diazo-1-(2-methoxyphenyl)ethanone 
• 79-37-8 oxalyl dichloride 
• 93-25-4 2-methoxyphenylacetic acid 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 135-02-4 ortho-anisaldehyde 
• 90-02-8 salicylaldehyde 

Downstream Products

• 351155-93-6 (2-methoxy-phenyl)-acetic acid-(3,4-dimethoxy-phenethylamide) 
• 5211-62-1 1-(2-methoxyphenyl)propan-2-one 
• 27432-39-9 1-(2-methoxyphenyl)butan-2-one 
• 101597-77-7 2-[(2-methoxy-phenyl)-acetoxy]-benzoic acid methyl ester 
• 53463-34-6 N,N-Di-sec-butyl-2-(2-methoxy-phenyl)-acetamide 
• 26994-43-4 6β-[2-(2-methoxy-phenyl)-acetylamino]-penicillanic acid 
• 32297-61-3 Allyl-N-(2-metoxyphenyl-acetyl)-2,6-dimethoxybenzohydroxamat 
• 32344-03-9 Aethyl-N-(2-methoxyphenylacetyl)-3-chlor-2,6-dimethoxybenzohydroxamat 
• 136559-44-9 2-(2-Methoxy-phenyl)-N,N-dipropyl-acetamide 
• 349134-81-2 2-(2-methoxyphenyl)-1-(piperidin-1-yl)ethan-1-one 
• 864445-43-2 JWH 250 
• 75256-37-0 4-hydroxy-3-(o-methoxyphenyl)-1,2-dihydroquinolin-2-one 
• 75256-43-8 4-Chloro-3-(2-methoxy-phenyl)-1H-quinolin-2-one 
• 74384-37-5 1-(4-Hydroxy-3,5-dimethyl-phenyl)-2-(2-methoxy-phenyl)-ethanone 

Relevant articles and documents

Design, synthesis, biological evaluation and silico prediction of novel sinomenine derivatives

Sinomenine is a morphinan alkaloid with a variety of biological activities. Its derivatives have shown significant cytotoxic activity against different cancer cell lines in many studies. In this study, two series of sinomenine derivatives were designed and synthesized by modifying the active positions C1 and C4 on the A ring of sinomenine. Twenty‐three compounds were synthesized and characterized by spectroscopy (IR,1H‐NMR,13C‐NMR, and HRMS). They were further evaluated for their cytotoxic activity against five cancer cell lines, MCF‐7, Hela, HepG2, SW480 and A549, and a normal cell line, Hek293, using MTT and CCK8 methods. The chlorine‐containing compounds exhibited significant cytotoxic activity compared to the nucleus structure of sinomenine. Furthermore, we searched for cancer‐related core targets and verified their interaction with derivatives through molecular docking. The chlorine‐containing compounds 5g, 5i, 5j, 6a, 6d, 6e, and 6g exhibited the best against four core targets AKT1, EGFR, HARS and KARS. The molecular docking results were consistent with the cytotoxic results. Overall, results indicate that chlorine‐containing derivatives might be a promising lead for the development of new anticancer agents.

Resolution of Vaulted Biaryl Ligands via Borate Esters of Quinine and Quinidine

Given the sudden and unexplained rise in the cost of (+)- A nd (-)-sparteine, an alternative method for the resolution of vaulted biaryls has been developed. This method involves the reaction of a racemic vaulted biaryl ligand with one equivalent of BH3·SMe2 and one equivalent of either quinine or quinidine. A precipitate then forms from the resulting mixture of diastereomeric borates as a result of differential solubilities. Hydrolysis of the precipitate then liberates the (S)-ligand in the case of quinine and the (R)-ligand in the case of quinidine, both with >99% ee. This method has been applied to 16 different vaulted biaryl ligands, including 10 whose preparation is described here for the first time. In addition, proof of principle has been demonstrated for the dynamic thermodynamic resolution of the vaulted biaryl ligands with this method in combination with a nonchiral copper(II) complex that can racemize the ligand.

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.